首页> 外文期刊>American Journal of Translational Research >Clinical efficacy of jade wind-barrier powder combined with loratadine in the treatment of pediatric allergic rhinitis
【24h】

Clinical efficacy of jade wind-barrier powder combined with loratadine in the treatment of pediatric allergic rhinitis

机译:玉风阻隔粉联合LorataDine治疗儿科过敏性鼻炎的临床疗效

获取原文
           

摘要

Objective: To investigate the clinical efficacy of Jade Wind-Barrier Powder combined with Loratadine in the treatment of pediatric allergic rhinitis (PAR). Methods: The clinical data of 101 children with allergic rhinitis (AR) admitted to the Affiliated Hospital of Qingdao University and Affiliated Hospital of Nanjing University of Traditional Chinese Medicine from January 2019 to December 2019 were retrospectively analyzed. The children were randomly divided into Group A (n=50) and Group B (n=51) in accordance with a random number table. Group A was treated with Loratadine only, while Group B was treated with Loratadine combined with Jade Wind-Barrier powder. The clinical efficacy, symptom disappearance time, symptom scores before and after treatment, indices of immunological function, changes in the indices of inflammatory factors and disease recurrence were compared between the two groups. Results: The overall response rate (ORR) in Group B (96.08%) was higher than that in Group A (76.00%) ( P 0.05). The disappearance time of sneezing, stuffy nose, runny nose and itchy nose in Group B was shorter than that in Group A ( P 0.05). After treatment, Group B exhibited lower symptom scores for sneezing, stuffy nose, runny nose and itchy nose, lower levels of IL-13, IL-4 and TNF-α, and higher CD4 + CD25 + , CD19 + and CD8 + than Group A ( P 0.05). The recurrence rate in Group B (3.92%) was lower than that in Group A (26.00%) ( P 0.05). Conclusion: Jade Wind-Barrier powder combined with Loratadine can improve clinical symptoms, immunity, inflammation levels and disease recurrence rate of PAR patients, with a significant clinical efficacy.
机译:目的:探讨玉风屏障粉联合LorataDine治疗儿科过敏性鼻炎(PAR)的临床疗效。方法:回顾性分析了2019年1月至2019年1月南京中医药附属医院接受过敏鼻炎(AR)的101例过敏鼻炎(AR)的临床资料。根据随机数表随机分为A(n = 50)和B组(n = 51)的子项。 A组仅使用LorataDine治疗,而B组被加拉拉汀与玉风屏障粉联合使用。临床疗效,症状消失时间,治疗前后的症状评分,免疫功能指标,两组之间的炎症因子和疾病复发索引的变化。结果:B组(96.08%)的总反应率(ORR)高于A(76.00%)(P <0.05)。 B组中打喷嚏,鼻塞,流鼻涕和痒鼻涕的消失时间短于A组(P <0.05)。治疗后,B组呈症状分数较低,用于打喷嚏,鼻塞,流鼻涕和瘙痒,较低的IL-13,IL-4和TNF-α,更高的CD4 + CD25 +,CD19 +和CD8 +而不是组a(p <0.05)。 B组(3.92%)的复发率低于A组(26.00%)(P <0.05)。结论:玉风屏障粉联合洛拉啶可提高临床症状,免疫力,炎症水平和疾病复发率,具有显着的临床疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号